280 related articles for article (PubMed ID: 27130072)
1. Angiogenic balance (sFlt-1/PlGF) and preeclampsia.
Lecarpentier E; Tsatsaris V
Ann Endocrinol (Paris); 2016 Jun; 77(2):97-100. PubMed ID: 27130072
[TBL] [Abstract][Full Text] [Related]
2. Placental growth factor (PlGF) and sFlt-1 during pregnancy: physiology, assay and interest in preeclampsia.
Lecarpentier É; Vieillefosse S; Haddad B; Fournier T; Leguy MC; Guibourdenche J; Tsatsaris V
Ann Biol Clin (Paris); 2016 Jun; 74(3):259-67. PubMed ID: 27237799
[TBL] [Abstract][Full Text] [Related]
3. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension.
Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ
Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016
[TBL] [Abstract][Full Text] [Related]
4. Pro-angiogenic therapeutics for preeclampsia.
Eddy AC; Bidwell GL; George EM
Biol Sex Differ; 2018 Aug; 9(1):36. PubMed ID: 30144822
[TBL] [Abstract][Full Text] [Related]
5. Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension.
Spradley FT; Tan AY; Joo WS; Daniels G; Kussie P; Karumanchi SA; Granger JP
Hypertension; 2016 Apr; 67(4):740-7. PubMed ID: 26831193
[TBL] [Abstract][Full Text] [Related]
6. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
[TBL] [Abstract][Full Text] [Related]
7. VEGF (Vascular Endothelial Growth Factor) Functionalized Magnetic Beads in a Microfluidic Device to Improve the Angiogenic Balance in Preeclampsia.
Trapiella-Alfonso L; Alexandre L; Fraichard C; Pons K; Dumas S; Huart L; Gaucher JF; Hebert-Schuster M; Guibourdenche J; Fournier T; Vidal M; Broutin I; Lecomte-Raclet L; Malaquin L; Descroix S; Tsatsaris V; Gagey-Eilstein N; Lecarpentier E
Hypertension; 2019 Jul; 74(1):145-153. PubMed ID: 31079531
[TBL] [Abstract][Full Text] [Related]
8. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
[TBL] [Abstract][Full Text] [Related]
9. Dysregulation of anti-angiogenic agents (sFlt-1, PLGF, and sEndoglin) in preeclampsia--a step forward but not the definitive answer.
Foidart JM; Schaaps JP; Chantraine F; Munaut C; Lorquet S
J Reprod Immunol; 2009 Nov; 82(2):106-11. PubMed ID: 19853925
[TBL] [Abstract][Full Text] [Related]
10. The role of disordered angiogenesis tissue markers (sflt-1, Plgf) in present day diagnosis of preeclampsia.
Kwiatkowski S; Kwiatkowska E; Torbe A
Ginekol Pol; 2019; 90(3):173-176. PubMed ID: 30950008
[TBL] [Abstract][Full Text] [Related]
11. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
Maynard SE; Min JY; Merchan J; Lim KH; Li J; Mondal S; Libermann TA; Morgan JP; Sellke FW; Stillman IE; Epstein FH; Sukhatme VP; Karumanchi SA
J Clin Invest; 2003 Mar; 111(5):649-58. PubMed ID: 12618519
[TBL] [Abstract][Full Text] [Related]
12. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
[TBL] [Abstract][Full Text] [Related]
13. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
Vatten LJ; Åsvold BO; Eskild A
Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
[TBL] [Abstract][Full Text] [Related]
14. The relationship of angiogenic factors to maternal and neonatal manifestations of early-onset and late-onset preeclampsia.
Pinheiro CC; Rayol P; Gozzani L; Reis LM; Zampieri G; Dias CB; Woronik V
Prenat Diagn; 2014 Nov; 34(11):1084-92. PubMed ID: 24916790
[TBL] [Abstract][Full Text] [Related]
15. An intermediate sFlt-1/PlGF ratio indicates an increased risk for adverse pregnancy outcome.
Hoffmann J; Ossada V; Weber M; Stepan H
Pregnancy Hypertens; 2017 Oct; 10():165-170. PubMed ID: 29153672
[TBL] [Abstract][Full Text] [Related]
16. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
[TBL] [Abstract][Full Text] [Related]
17. Circulating angiogenic factors and the risk of preeclampsia.
Levine RJ; Maynard SE; Qian C; Lim KH; England LJ; Yu KF; Schisterman EF; Thadhani R; Sachs BP; Epstein FH; Sibai BM; Sukhatme VP; Karumanchi SA
N Engl J Med; 2004 Feb; 350(7):672-83. PubMed ID: 14764923
[TBL] [Abstract][Full Text] [Related]
18. The perinatal implications of angiogenic factors.
Smith GC; Wear H
Curr Opin Obstet Gynecol; 2009 Apr; 21(2):111-6. PubMed ID: 19996864
[TBL] [Abstract][Full Text] [Related]
19. A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia.
Sahay AS; Patil VV; Sundrani DP; Joshi AA; Wagh GN; Gupte SA; Joshi SR
Hypertens Res; 2014 Aug; 37(8):753-8. PubMed ID: 24718301
[TBL] [Abstract][Full Text] [Related]
20. The association between angiogenic markers and fetal sex: Implications for preeclampsia research.
Andersen LB; Jørgensen JS; Herse F; Andersen MS; Christesen HT; Dechend R
J Reprod Immunol; 2016 Sep; 117():24-9. PubMed ID: 27359072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
